TCGA-OR-A5KW-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.411
- MTORC1_SIGNALING+0.357
- PEROXISOME+0.301
- PANCREAS_BETA_CELLS+0.298
- UNFOLDED_PROTEIN_RESPONSE+0.286
- GLYCOLYSIS+0.259
- E2F_TARGETS+0.226
- ANDROGEN_RESPONSE+0.214
- ADIPOGENESIS+0.197
- MYC_TARGETS_V1+0.186
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.344
- APICAL_SURFACE-0.327
- INFLAMMATORY_RESPONSE-0.290
- IL2_STAT5_SIGNALING-0.249
- WNT_BETA_CATENIN_SIGNALING-0.228
- TGF_BETA_SIGNALING-0.224
- IL6_JAK_STAT3_SIGNALING-0.145
- KRAS_SIGNALING_UP-0.128
- COMPLEMENT-0.110
- APOPTOSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01024 | — | cohortA1 | 0.753 |
| 2 | SRR1313126 | — | C | 0.727 |
| 3 | SRR1516095 | — | — | 0.715 |
| 4 | SRR29022841 | — | C | 0.713 |
| 5 | TCGA-78-7154-01A-11R-2039-07 | — | cohortA4 | 0.710 |
| 6 | GSM5359435 | — | — | 0.710 |
| 7 | SRR13311171 | — | — | 0.706 |
| 8 | SRR8518248 | — | E | 0.704 |
| 9 | MBCProject_0243_T2_RNA | — | C | 0.700 |
| 10 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.698 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.411 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.357 | Inavolisib | — uncovered |
| PEROXISOME | 0.301 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.298 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.286 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.259 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.226 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.214 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.197 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.186 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.186 | Idelalisib | — uncovered |
| HYPOXIA | 0.182 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.169 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.165 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.159 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.141 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.137 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.136 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.128 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.088 | Idelalisib | — uncovered |